首页> 外文期刊>Journal of drugs in dermatology: JDD >A phase IV, open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris
【24h】

A phase IV, open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris

机译:IV期开放标签研究,评估中度至重度痤疮患者三联疗法与米诺环素HCl缓释片,局部抗生素/类维生素A制剂和过氧化苯甲酰的配合使用

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Moderate to severe acne vulgaris is often treated with a combination of an oral antibiotic, topical antibiotic/retinoid, and benzoyl peroxide (BP), but data are limited on the efficacy of this and other combination regimens that incorporate both oral and topical therapies. Methods: Patients were required to be aged 12-30 years with moderate to severe acne (grades 3-4 acne on the Investigator's Global Assessment [IGA]) and deemed potential candidates for treatment with isotretinoin. Enrolled patients were given triple-combination therapy, defined in this study as oral minocycline HCl extended release ?1 mg/kg QD, 6% BP foaming cloths used QD, and clindamycin phosphate 1.2%/tretinoin 0.025% gel applied QD, and were evaluated at baseline and weeks 2, 4, 8, and 12. Results: A total of 97 patients were enrolled in the study. At week 12, 89% of patients had at least a one-grade improvement from baseline IGA and 96% had at least a one-grade improvement from baseline Global Aesthetic Improvement Scale score. Mean±SD inflammatory, non-inflammatory, and total lesion counts decreased from baseline by 61.8%±38.3%, 48.8%±34.5%, and 56.5%±29.9%, respectively. The percentage of patients evaluated as candidates for isotretinoin by independent photographic review was 77% (69/90) at baseline and only 16% (14/90) at week 12. Treatment-related adverse events (AEs) occurred in eight of 97 (8%) patients. Triple-combination therapy was not associated with any serious AEs or AEs leading to discontinuation. Conclusion: Triple-combination therapy was well tolerated and substantially reduced facial acne lesion counts, with 84% of patients judged to no longer be candidates for isotretinoin therapy by study end. These data support the clinical observation that a triple-combination regimen incorporating oral minocycline (dosed by patient weight), BP foaming cloths 6% QD, and clindamycin phosphate 1.2%/tretinoin 0.025% gel QD can substantially improve moderate to severe acne vulgaris.
机译:背景:中度至重度寻常痤疮通常通过口服抗生素,局部抗生素/类维甲酸和过氧化苯甲酰(BP)的组合进行治疗,但该方法以及其他结合口服和局部治疗的联合治疗方案的疗效数据有限。方法:要求患者年龄在12至30岁之间,患有中度至重度痤疮(研究人员全球评估[IGA]评估为3-4级痤疮),并被视为可能使用异维A酸治疗的候选人。纳入研究的患者接受了三联疗法,在本研究中定义为口服米诺环素HCl缓释≥1 mg / kg QD,6%BP泡沫布采用QD,克林霉素磷酸酯1.2%/维甲酸0.025%凝胶采用QD,并进行了评估在基线以及第2、4、8和12周时。结果:共有97名患者参加了研究。在第12周时,有89%的患者较基线IGA改善了至少一个等级,而96%的患者较基线整体美学改善量表评分至少了一个等级。平均±SD炎性,非炎性和总病变计数分别比基线降低61.8%±38.3%,48.8%±34.5%和56.5%±29.9%。通过独立的影像学评估,评估为异维A酸候选药物的患者在基线时为77%(69/90),在第12周时仅为16%(14/90)。在97个患者中有8个发生了与治疗相关的不良事件(AEs)( 8%)的患者。三联疗法与任何严重的不良事件或导致停药的不良事件无关。结论:三联疗法耐受性良好,面部痤疮病变计数大大降低,到研究结束时,有84%的患者被判定不再是异维A酸疗法的候选者。这些数据支持以下临床观察:三联疗法结合口服米诺环素(按患者体重确定),BP泡沫布6%QD和磷酸克林霉素1.2%/维甲酸0.025%凝胶QD可以显着改善中度至重度寻常痤疮。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号